Here are the S-1 registration statements from Dare Bioscience, Inc. (DARE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow DARE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DARE filings page.
Daré Bioscience, Inc. (DARE) has filed a Form S-1 to register for resale up to 8,934,345 shares of common stock issued or issuable to investors and the placement agent from an August 2026 financing. All shares are being offered by selling stockholders; Daré is not selling shares in this registration.
The registered shares consist of 8,759,162 shares underlying Series A and Series B common warrants (including pre-funded warrants) and 175,183 shares underlying placement agent warrants. Daré will not receive proceeds from stockholder resales, but could receive up to about $12.4 million if all warrants are exercised for cash, which it plans to use for working capital, 503B compounding and consumer health initiatives, and R&D.
Daré describes a women’s health portfolio spanning contraception, menopause, sexual and vaginal health, and infectious disease, plus a dual-path model using both FDA approval and Section 503B compounding. It highlights new 503B and consumer products, significant ongoing capital needs, a recent Nasdaq Listing Rule 5550(b) deficiency under review by a Nasdaq hearing panel, and an auditor’s going-concern paragraph in its 2025 financial statements.